Quantcast

Latest Cordis Stories

2012-09-12 23:03:39

Research reveals an aging population and increasing obesity rates fuel the €1.1 Billion dollar Endovascular devices market in Europe. (PRWEB) September 11,

2012-02-15 12:45:00

Survey Reveals Most Cardiologists Would Use a Bioabsorbable Stent for Coronary Angioplasty According to iData Research Vancouver, BC (PRWEB) February 15, 2012

2011-06-15 08:01:00

NEW BRUNSWICK, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that it expects to record an after-tax restructuring charge in the range of $500-$600 million in the second quarter of 2011 as a result of restructuring plans announced by its subsidiary, Cordis Corporation.

2011-06-15 08:00:00

BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO(TM) Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists.

2011-05-16 08:00:00

PARIS, May 16, 2011 /PRNewswire/ -- Cordis announces the launch in Europe of Radial Solutions, a complete portfolio for transradial interventions.

2011-05-16 08:00:00

PARIS, May 16, 2011 /PRNewswire/ -- - Cordis Continues its History of Innovation With Two New Products: EMPIRA(TM) and RADIALSOURCE(TM) Cordis announced it has obtained CE mark for its EMPIRA(TM) and EMPIRA(TM) NC RX PTCA* Dilatation Catheters for the treatment of coronary artery disease.

2011-01-28 14:59:00

MARSHALL, Texas, Jan. 28, 2011 /PRNewswire/ -- A federal jury in Marshall, Texas has returned a $482 million verdict for Dickstein Shapiro LLP client Dr. Bruce N. Saffran against defendants Johnson & Johnson and its subsidiary, Cordis Corporation, in Saffran v.


Word of the Day
cespitose
  • Growing in low tufty patches.
The word 'cespitose' comes from a Latin word meaning 'turf'.
Related